Projects related to 6-2019-6708

Results Found (32)
Technology NameBriefcaseLead Researcher
Background: Dental disorders occur when there are changes in oral hygiene, diet, medicaments or age. Our Innovation Novel dental coating that delivers therapeutics over time, as required, in response to sensed changes in acidic/basic conditions ...
More
Friedman Michael
  Background With advances in biotechnology, nasal drug delivery is increasingly becoming a more viable alternative to oral and injectable routes of administration for an increasing number of drugs, including peptides. Our Innovation Platform ...
More
Touitou Elka
Background Most active pharmaceutical ingredients (APIs) are not suitable for “passive” loading into nano-liposomes. The desired concentration in the nano-liposomes is hard to achieve. Consequently, the therapeutic efficacy in humans is not ...
More
Goldblum Amiram
Background Emulsification in aqueous media is not effective for the encapsulation of hydrophilic drugs. Peptides and proteins may deteriorate when exposed to aqueous-organic interfaces Neuropeptides are potent CNS neuromodulators and have many ...
More
Domb Abraham
Background Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) are leading causes of blindness in the Western world. Both are characterized by pathological angiogenesis in the various eye structures. With high prevalence  in  ...
More
Willner Itamar
  Additional information will be provided upon request
More
Domb Abraham
Background  Micro-emulsions are formed more or less spontaneously when their components are brought into contact.  They have been the only successful delivery systems for certain types of pharmaceutical compounds, particularly compounds such as ...
More
Domb Abraham
Background Current preclinical and clinical data indicate that there is negligible release of drug from circulating liposomes. Once liposomes extravagate to extracellular tissue fluids, little is known of the processes determining drug release. ...
More
Barenholz Yechezkel
Background Emulsification in aqueous media is not effective for the encapsulation of hydrophilic drugs. Peptides and proteins may deteriorate when exposed to aqueous-organic interfaces Neuropeptides are potent CNS neuromodulators and have many ...
More
Domb Abraham
Background        Many of today’s leading compounds and drugs in pipeline fail to reach clinical stages due to poor oral bioavailability. In addition, Increase in oral bioavailability leads a lower inter and intra subject variability. Our ...
More
Domb Abraham
Background The release of targeted drugs is often achieved by attaching the drug load to a carrier through specific peptide sequences which are cleaved by proteases that are highly expressed at the desired location. Cathepsins proteases, ...
More
Blum Galia
Background Peptides are key players in a variety of physiological and pathological processes and play very important roles in modulating various cell functions. One of the most important challenges developing peptide drugs is the lack of ...
More
Gilon Chaim
Background Multiple strategies exist for the targeted treatment of different cell pathologies. One ongoing challenge is the introduction of therapeutic molecules into cells. Current approaches rely on viral vectors, electroporation, or carriers. ...
More
Shenhar Roy
Once-daily, sustained-release Sirolimus delivery system Categories Oral Cavity, Oncology/Cancer, Sustained Release, Drug Delivery Development Stage Prototypes tested in vitro; pharmokinetic and pharmacodynamic testing in human volunteers ...
More
Friedman Michael
Background The physical size of protein drugs and their susceptibility to degradation are key determinates that make them more dependent on drug delivery technologies. However formulating protein delivery systems so that they maintain their ...
More
Barenholz Yechezkel
Oral Dosage Form for Immediate and Prolonged Action of Cannabinoids     Categories  Cannabinoids, Drug Delivery, Novel Carrier, Oral Formulation Development Stage In-vivo proof of concept Patent Status PCT patent application filed Market ...
More
Touitou Elka
  Current Development Stage TRL 9 Ready for mass production   Our Innovation Pouch drug delivery system (web- like films) for dermal, transdermal and nail  administration of drugs and actives for various treatments Applied to the nail or ...
More
Touitou Elka
  Categories Cannabinoid Administration, Formulation, Drug Delivery, Novel Carriers, Transdermal Formulation, Nasal Formulation, Oral formulation Development Stage In-vivo proof of concept Patent Status Several patent applications – new ...
More
Touitou Elka
  Categories Cannabinoids, Drug Delivery, Novel Carrier, Oral Formulation Development Stage In-vivo proof of concept Patent Status PCT patent application filed Market Improved delivery of cannabinoids is a real need and has an increasing ...
More
Touitou Elka
Keywords Innovative carrier, Nasal administration, Delivery to brain, Treatment of pain, disorders in Parkinson's disease, Multiple Sclerosis, Alzheimer, Epilepsy and brain trauma Current development stage Tested in animal model for ...
More
Touitou Elka
Application Prolonged epileptic seizures may lead to the development of life threatening cerebral state of a persistent seizure, referred as Status epilepticus (SE). Oral administration of anti-convulsants antiepileptic drugs (AEDs) as well ...
More
Bialer Meir
Background Valproic acid (VPA) is a first line antiepileptic and CNS drug (Epilepsy, neuropathic pain, bipolar disorders etc) Multivalent action of VPA is highly advantageous, promising improved efficacy with reduced side effects for ...
More
Bialer Meir
Background: Autism spectrum disorder (ASD) is one of the fastest growing developmental disability in the United States, represents a group of neurodevelopmental disorders characterized by impaired social interaction and communication as well as ...
More
Avraham Yosefa
 Background A bipolar disorder is a form of a depressive disease that characteristically involves cycles of depression and elation or mania. The disorder is often a chronic recurring condition deteriorating one’s quality of life. Valnoctamide ...
More
Bialer Meir
  Additional information will be provided upon request
More
Domb Abraham
  Background Neuro-protective drugs products of all types protect the brain and peripheral nervous system neurons from degeneration and injury by promoting neuronal survival, proliferation and differentiation. These products can be used in the ...
More
Tsvelikhovsky Dmitry
Background Agonists that bind well to the cannabinoid CB2 receptor and do not bind, or only bind weakly to the cannabinoid CB1 receptor are very promising therapeutic compounds for a wide range of disorders. CB1 agonists (such as the ...
More
Mechoulam Raphael
Background Parkinson’s Disease (PD) is a progressive neurodegenerative disease caused by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). As the disease progresses the number of dopaminergic neurons decreases. ...
More
Atlas Daphne
Background  Parkinson disease (PD) is a long-term, progressive neurodegenerative disorder of the central nervous system, which results in motor and non-motor dysfunction. The disease is primarily related to loss of dopaminergic ...
More
Sharon Ronit